On September 8 local time, AstraZeneca, a British pharmaceutical giant, announced that it had suspended all vaccine trials of its new crown vaccine azd1222 project in the world due to serious adverse reactions in a vaccinated subject. According to British media reports, on September 10 local time, subjects with AstraZeneca’s new crown vaccine disclosed adverse reactions after the trial. < p > < p > according to the subjects, he received the first dose of vaccine in May this year, and 14 hours later, he began to have chills, headache and weakness, and had a high fever of 39 degrees. < / P > < p > “I went around 2:00 a.m. I was chilly and my temperature was as high as 39 degrees. I was very weak and couldn’t get up and move.” At the same time, he developed severe headache and fatigue reaction, which began to ease three days after vaccination, but still felt weak. After the successful trials in the first and second stages, AstraZeneca is considered to be one of the first batch of vaccines to be put on the market. Now, it has become the first batch of vaccine candidates in the world that has been suspended and has entered phase III clinical trial. < p > < p > on the evening of September 10, the head of China biology, Sinopharm group, said that the two new crown inactivated vaccines developed by Sinopharm China biology had been inoculated hundreds of thousands of times, without any obvious adverse reactions and infection. Moreover, tens of thousands of people who went to overseas high-risk countries and regions after vaccination have achieved zero infection so far. Global Tech